Furthermore, TIGIT-expressing CD4+ T cells represent a tumor-supportive T cell subset in CLL [35] and TIGIT blockade can restore CD8+ T-cell immunity against multiple myeloma (MM) [60]. Here, CD4 is linked to B-cell chronic lymphocytic leukemia.